A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma

Introduction: Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment of patients with malignant melanoma. However, improving therapeutic efficacy requires identifying drug combinations that elicit durable responses without inducing intolerable toxicity. Within that context, se...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Mohamed A. Gouda, Bettzy Stephen, Yanyan Tian, Anas Alshawa, Dilichukwu O. Chudy Onwugaje, Aya Albittar, Yali Yang, Abdulrazzak Zarifa, Bulent Yilmaz, Serdar Gurses, Ashabari Sprenger, Mohamed H. Derbala, Amanda Brink, Jeffrey Andrew How, Justin Moyers, Sarina A. Piha-Paul, David S. Hong, Funda Meric-Bernstam, Sapna P. Patel, Isabella Glitza Oliva
Format:	Artigo
Sprog:	Inglês
Udgivet:	Innovative Healthcare Institute 2024-11-01
Serier:	Journal of Immunotherapy and Precision Oncology
Fag:	selinexor immune checkpoint inhibitors melanoma
Online adgang:	https://jipo.org/doi/pdf/10.36401/JIPO-24-3
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!